ABSTRACT
Background The mechanism driving multiple pathophysiological alterations in Alzheimer’s disease (AD) remains unclear. Thiamine deficiency, a well-known feature of AD, may contribute to these alterations.
Methods The expressions of four known genes associated with thiamine metabolism were studied in brain samples from patients with AD and other neurodegenerative disorders. The results were further demonstrated in AD and diabetic mouse and cellular models. The phenotypes of mice with conditional Thiamine pyrophosphokinase-1 (Tpk) knockout in brain excitatory neurons were investigated. The therapeutic effects of thiamine diphosphate supplement and Tpk delivery on cellular and mouse models were explored. Phase 2 clinical trial of benfotiamine, a thiamine derivative, plus donepezil was performed.
Results Only TPK expression was inhibited in brain samples of AD patients, while none of thiamine-associated genes were significantly changed in other neurodegenerative disorders. TPK inhibition in the brains and neurons was verified in AD and diabetic mouse and cellular models. Mice with Tpk deletion in neurons exhibited all major pathophysiological alterations of AD, including amyloid deposition, Tau hyperphosphorylation, and brain atrophy. TPK expression restoration and thiamine diphosphate supplement ameliorated the pathophysiological and behavioral phenotypes in mouse and cell models with Tpk insufficiency. Benfotiamine delayed cognitive decline in mild-to-moderate AD patients with a dose-effect relationship, particularly with a significant attenuation of the deterioration in moderate AD patients by post hoc analysis.
Conclusions TPK deficiency and hence thiamine diphosphate reduction in neurons are a decisive factor driving multiple pathophysiologic alterations of AD, unveiling a new direction for the disease mechanism and treatment.
Competing Interest Statement
Chunjiu Zhong, one of the corresponding authors, holds shares of Shanghai Raising Pharmaceutical Co., Ltd., which is dedicated to developing drugs for the prevention and treatment of AD. The other authors declare that they have no competing interests.
Clinical Trial
CTR20171631
Funding Statement
This study was supported by grants from the Shanghai Municipal Science and Technology Major Project, the National Natural Science Foundation of China (81870822, 91332201, 81901081, 81600930, 32100826), and China Postdoctoral Science Foundation (2022M710775).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol in accordance with Good Clinical Practice guidelines and the principles of Declaration of Helsinki was approved by the Committee of Medical Ethics of Huashan Hospital, Fudan University, the leading hospital of this trial, as well as by relevant local institutional review boards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵$ A complete list of the benfotiamine phase 2 trial investigators is provided in the supplementary appendix.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
